Drug Approval | February 26, 2022
Japan approves Keytruda plus Lenvima for two types of cancer
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
The recently released WHO guideline on hypertension treatment (2021), recommends that patients with stable blood pressure can be asked to visit clinics at 3-6 month intervals as an important strategy to improve hypertension control
Bangladesh, Indonesia, Pakistan, Serbia and Vietnam to receive mRNA technology from the technology transfer hub
Heterologous booster vaccination refers to the use of vaccine boosters from different technology platforms from the prime vaccines, which could improve the overall immune response and enhance protection against other variants
DS-5670 is an mRNA vaccine against Covid-19 using a novel nucleic acid delivery technology discovered by the company
It would be the first protein-based alternative available in Israel
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
The brand is now available pan-India through their distribution partner
Subscribe To Our Newsletter & Stay Updated
